US4855231A
(en)
*
|
1984-10-30 |
1989-08-08 |
Phillips Petroleum Company |
Regulatory region for heterologous gene expression in yeast
|
US4885242A
(en)
*
|
1984-10-30 |
1989-12-05 |
Phillips Petroleum Company |
Genes from pichia histidine pathway and uses thereof
|
US4818700A
(en)
*
|
1985-10-25 |
1989-04-04 |
Phillips Petroleum Company |
Pichia pastoris argininosuccinate lyase gene and uses thereof
|
US4882279A
(en)
*
|
1985-10-25 |
1989-11-21 |
Phillips Petroleum Company |
Site selective genomic modification of yeast of the genus pichia
|
US4895800A
(en)
*
|
1985-11-26 |
1990-01-23 |
Phillips Petroleum Company |
Yeast production of hepatitis B surface antigen
|
ZA872534B
(en)
*
|
1986-05-08 |
1987-11-25 |
Phillips Petroleum Co |
Yeast production of streptokinase
|
US5258287A
(en)
*
|
1988-03-22 |
1993-11-02 |
Genentech, Inc. |
DNA encoding and methods of production of insulin-like growth factor binding protein BP53
|
IL89991A0
(en)
*
|
1988-04-25 |
1989-12-15 |
Phillips Petroleum Co |
Expression of hepatitis b pres2 protein in methylotrophic yeasts
|
IL89989A0
(en)
*
|
1988-04-25 |
1989-12-15 |
Phillips Petroleum Co |
Expression of human interleukin-2 in methylotrophic yeasts
|
US5204252A
(en)
*
|
1989-02-08 |
1993-04-20 |
Henkel Research Corporation |
Candida tropicalis transformation system
|
AU5196290A
(en)
*
|
1989-02-13 |
1990-09-05 |
Salk Institute Biotechnology/Industrial Associates, Inc., The |
Production of superoxide dismutase in pichia pastoris yeast cells
|
US5254466A
(en)
*
|
1989-11-06 |
1993-10-19 |
Henkel Research Corporation |
Site-specific modification of the candida tropicals genome
|
US5612198A
(en)
*
|
1990-09-04 |
1997-03-18 |
The Salk Institute |
Production of insulin-like growth factor-1 in methylotrophic yeast cells
|
WO1992013951A1
(en)
*
|
1991-02-04 |
1992-08-20 |
The Salk Institute Biotechnology/Industrial Associates, Inc. |
Production of human serum albumin in methylotrophic yeast cells
|
JPH06506117A
(ja)
*
|
1991-04-01 |
1994-07-14 |
メルク エンド カンパニー インコーポレーテッド |
ピキア(Pichia)蛋白質分解活性に影響する遺伝子およびその使用
|
US6872550B1
(en)
*
|
1991-07-11 |
2005-03-29 |
Baxter Vaccine Ag |
Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
|
US5665600A
(en)
*
|
1991-09-18 |
1997-09-09 |
Research Corporation Technologies, Inc. |
Pichia pastoris linear plasmids and DNA fragments thereof
|
DK0643772T3
(da)
|
1992-06-03 |
1998-02-02 |
Genentech Inc |
Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
|
WO1994020631A2
(en)
*
|
1993-03-03 |
1994-09-15 |
E.I. Du Pont De Nemours And Company |
Production of glycolate oxidase in methylotrophic yeast
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
CA2202351A1
(en)
*
|
1994-10-18 |
1996-04-25 |
George Phillip Vlasuk |
Nematode-extracted serine protease inhibitors and anticoagulant proteins
|
US5866543A
(en)
*
|
1995-06-05 |
1999-02-02 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US5863894A
(en)
*
|
1995-06-05 |
1999-01-26 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US6090916A
(en)
*
|
1994-10-18 |
2000-07-18 |
Corvas International, Inc. |
Nematode-extracted serine protease inhibitors and anticoagulant proteins
|
US5866542A
(en)
*
|
1994-10-18 |
1999-02-02 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US5872098A
(en)
*
|
1995-06-05 |
1999-02-16 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
US5945275A
(en)
*
|
1994-10-18 |
1999-08-31 |
Corvas International, Inc. |
Nematode-extracted anticoagulant protein
|
EP1382679A3
(en)
|
1995-09-08 |
2004-11-10 |
Genentech, Inc. |
Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists
|
JP2000500014A
(ja)
*
|
1995-11-09 |
2000-01-11 |
ザイモジェネティクス,インコーポレイティド |
ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法
|
US5955349A
(en)
*
|
1996-08-26 |
1999-09-21 |
Zymogenetics, Inc. |
Compositions and methods for producing heterologous polypeptides in Pichia methanolica
|
US5716808A
(en)
*
|
1995-11-09 |
1998-02-10 |
Zymogenetics, Inc. |
Genetic engineering of pichia methanolica
|
JP2000503204A
(ja)
|
1996-01-08 |
2000-03-21 |
ジェネンテック インコーポレーテッド |
Wsxレセプター及びリガンド類
|
US5736383A
(en)
*
|
1996-08-26 |
1998-04-07 |
Zymogenetics, Inc. |
Preparation of Pichia methanolica auxotrophic mutants
|
CN1230997A
(zh)
*
|
1996-07-17 |
1999-10-06 |
津莫吉尼蒂克斯公司 |
甲醇毕赤酵母的转化
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
MX9605082A
(es)
|
1996-10-24 |
1998-04-30 |
Univ Autonoma De Nuevo Leon |
Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
|
US6100076A
(en)
|
1997-01-31 |
2000-08-08 |
Genentech, Inc. |
O-fucosyltransferase
|
AU729158B2
(en)
|
1997-01-31 |
2001-01-25 |
Genentech Inc. |
O-fucosyltransferase
|
ES2256935T3
(es)
|
1997-04-07 |
2006-07-16 |
Genentech, Inc. |
Anticuerpos humanizadores y procedimiento para producirlos.
|
AU743758B2
(en)
|
1997-04-07 |
2002-02-07 |
Genentech Inc. |
Anti-VEGF antibodies
|
US6265186B1
(en)
|
1997-04-11 |
2001-07-24 |
Dsm N.V. |
Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
AU1288399A
(en)
|
1997-10-29 |
1999-05-17 |
Genentech Inc. |
Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
|
EP1029046B1
(en)
|
1997-10-29 |
2008-09-24 |
Genentech, Inc. |
Wnt-1 inducible genes
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
ATE365800T1
(de)
|
1998-05-15 |
2007-07-15 |
Genentech Inc |
Therapeutische verwendungen von il-17 homologe polypeptide
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6316245B1
(en)
*
|
1998-09-16 |
2001-11-13 |
Biongene Co., Ltd. |
Mutant cells of Pichia
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
EP1484338B1
(en)
|
1998-12-22 |
2007-02-07 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
EP1141024B1
(en)
|
1999-01-15 |
2018-08-08 |
Genentech, Inc. |
POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
|
US6720174B1
(en)
|
1999-01-28 |
2004-04-13 |
Novozymes A/S |
Phytases
|
EP1953173B1
(en)
|
1999-06-15 |
2009-11-18 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
|
CN101518653B
(zh)
|
1999-06-25 |
2015-08-19 |
基因技术股份有限公司 |
使用抗ErbB抗体-类美坦素偶联物的治疗方法
|
WO2001029078A2
(en)
*
|
1999-10-15 |
2001-04-26 |
Heska Corporation |
Method for production and use of mite group 1 proteins
|
EP1666494A1
(en)
|
1999-12-01 |
2006-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
EP1897946B1
(en)
|
1999-12-23 |
2012-07-11 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
WO2001077351A1
(en)
*
|
2000-04-07 |
2001-10-18 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Vectors and methods for dual protein expression in pichia pastoris and escherichia coli
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US7625756B2
(en)
|
2000-06-28 |
2009-12-01 |
GycoFi, Inc. |
Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
|
ES2252261T3
(es)
*
|
2000-06-28 |
2006-05-16 |
Glycofi, Inc. |
Metodos para producir glicoproteinas modificadas.
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US7598055B2
(en)
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
US8697394B2
(en)
*
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
AU2001277658B2
(en)
|
2000-06-30 |
2006-10-19 |
Research Corporation Technologies, Inc. |
Protein glycosylation modification in pichia pastoris
|
US7009045B2
(en)
*
|
2000-07-14 |
2006-03-07 |
Archer-Daniels-Midland Company |
Transformation systems for flavinogenic yeast
|
DK1303293T3
(da)
|
2000-07-27 |
2009-03-30 |
Genentech Inc |
Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
|
ATE412009T1
(de)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
US7265208B2
(en)
|
2001-05-01 |
2007-09-04 |
The Regents Of The University Of California |
Fusion molecules and treatment of IgE-mediated allergic diseases
|
EP1487480B1
(en)
|
2001-05-01 |
2015-10-07 |
The Regents of The University of California |
Fusion molecules for treatment of immune diseases
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
PT2000545E
(pt)
|
2001-06-20 |
2011-12-21 |
Genentech Inc |
Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
|
KR101008734B1
(ko)
|
2001-08-29 |
2011-01-14 |
제넨테크, 인크. |
유사분열촉진 활성을 가진 Bv8 핵산 및 폴리펩티드
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
CA2471431A1
(en)
|
2002-01-02 |
2003-07-17 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
JP2005535290A
(ja)
|
2002-02-22 |
2005-11-24 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
NZ535925A
(en)
|
2002-04-16 |
2008-06-30 |
Genentech Inc |
An isolated antibody that binds to a particular polypeptide
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003243400B2
(en)
|
2002-06-07 |
2009-10-29 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
IL165717A0
(en)
|
2002-06-26 |
2006-01-15 |
Flanders Interuniversity Inst |
A strain of methylotrophic yeast for producing proteins
|
ES2376165T3
(es)
|
2002-07-15 |
2012-03-09 |
F. Hoffmann-La Roche Ag |
Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
|
CA2497334A1
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
EP1543038B2
(en)
|
2002-09-11 |
2020-08-05 |
Genentech, Inc. |
Protein purification
|
ES2357505T3
(es)
|
2002-09-11 |
2011-04-27 |
Genentech, Inc. |
Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
|
WO2004024097A2
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2004028479A2
(en)
|
2002-09-25 |
2004-04-08 |
Genentech, Inc. |
Nouvelles compositions et methodes de traitement du psoriasis
|
CA2503330A1
(en)
|
2002-10-29 |
2004-05-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2003295401B2
(en)
|
2002-11-08 |
2010-04-29 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
EP2311870A1
(en)
|
2002-11-26 |
2011-04-20 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
DE60335602D1
(de)
*
|
2002-12-18 |
2011-02-17 |
Roche Diagnostics Gmbh |
Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
|
ATE387494T1
(de)
*
|
2002-12-20 |
2008-03-15 |
Hoffmann La Roche |
Hitzelabile desoxyribonuklease i-varianten
|
EP1585768A2
(en)
|
2003-01-23 |
2005-10-19 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
EP2526960A1
(en)
|
2003-03-12 |
2012-11-28 |
Genentech, Inc. |
Use of BV8 and/or EG-VEGF to promote hematopoiesis
|
EP1460425A1
(en)
*
|
2003-03-17 |
2004-09-22 |
Boehringer Mannheim Gmbh |
Deglycosylated enzymes for conjugates
|
LT2335725T
(lt)
|
2003-04-04 |
2017-01-25 |
Genentech, Inc. |
Didelės koncentracijos antikūno ir baltymo kompozicijos
|
CN1829741A
(zh)
|
2003-05-30 |
2006-09-06 |
健泰科生物技术公司 |
利用抗-vegf抗体的治疗
|
EA008831B1
(ru)
|
2003-06-12 |
2007-08-31 |
Эли Лилли Энд Компани |
Слитые белки аналогов glp-1
|
EP2277908A3
(en)
|
2003-07-08 |
2011-12-14 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CN1871351B
(zh)
|
2003-08-25 |
2010-06-23 |
富诺齐梅生物技术股份有限公司 |
一种新的真菌蛋白及其编码核酸
|
DK2161283T3
(da)
|
2003-11-17 |
2014-09-01 |
Genentech Inc |
SAMMENSÆTNINGER OMFATTENDE ANTISTOFFER MOD CD79b, SOM ER KONJUGERET TIL ET VÆKSTINHIBERENDE MIDDEL ELLER ET CYTOTOKSISK MIDDEL, OG FREMGANGSMÅDER TIL BEHANDLING AF TUMOR AF HÆMATOPOIETISK OPRINDELSE
|
ATE455849T1
(de)
*
|
2003-12-05 |
2010-02-15 |
Hoffmann La Roche |
Rekombinante carboxypeptidase b und ihre aufreinigung
|
EP1704166B1
(en)
|
2004-01-07 |
2015-04-29 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
EP2325318A1
(en)
|
2004-02-13 |
2011-05-25 |
Novozymes A/S |
Protease variants
|
RU2429245C2
(ru)
|
2004-03-30 |
2011-09-20 |
Глаксо Груп Лимитед |
Иммуноглобулины
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
NZ552956A
(en)
|
2004-07-20 |
2010-03-26 |
Genentech Inc |
Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer
|
CA2586313C
(en)
|
2004-11-10 |
2016-03-08 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP2230517A1
(en)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
WO2006132788A2
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
EP1922410A2
(en)
|
2005-08-15 |
2008-05-21 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
ATE513921T1
(de)
|
2005-08-16 |
2011-07-15 |
Novo Nordisk As |
Verfahren zur herstellung reifer insulinpolypeptide
|
EP1926749B1
(en)
*
|
2005-09-14 |
2011-07-27 |
Sanofi-Aventis Deutschland GmbH |
Cleavage of precursors of insulins by a variant of trypsin
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
KR101442266B1
(ko)
|
2005-11-18 |
2014-11-04 |
그렌마크 파머수티칼스 에스. 아. |
항-알파2 인테그린 항체 및 이의 용도
|
EP1962584A2
(en)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
GB0525662D0
(en)
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
JP2009527227A
(ja)
|
2006-02-17 |
2009-07-30 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
AU2007227224A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
NZ596517A
(en)
|
2006-04-05 |
2013-06-28 |
Abbott Biotech Ltd |
Antibody purification
|
EP2007428A2
(en)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
EP2027291A2
(en)
|
2006-04-27 |
2009-02-25 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
JP2009537147A
(ja)
|
2006-05-15 |
2009-10-29 |
シー レーン バイオテクノロジーズ, エルエルシー |
インフルエンザウイルスに対する中和抗体
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
WO2007149567A2
(en)
|
2006-06-21 |
2007-12-27 |
Musc Foundation For Research Development |
Targeting complement factor h for treatment of diseases
|
JP5829004B2
(ja)
|
2006-06-30 |
2015-12-09 |
ノボ・ノルデイスク・エー/エス |
抗nkg2a抗体とその使用
|
JP5517619B2
(ja)
|
2006-08-18 |
2014-06-11 |
ノバルティス アーゲー |
Prlr特異的抗体およびその使用
|
WO2008037735A1
(en)
|
2006-09-27 |
2008-04-03 |
Novo Nordisk A/S |
Method for making maturated insulin polypeptides
|
US8444970B2
(en)
|
2006-10-27 |
2013-05-21 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
US7829674B2
(en)
|
2006-10-27 |
2010-11-09 |
Lpath, Inc. |
Compositions and methods for binding sphingosine-1-phosphate
|
SG176476A1
(en)
|
2006-11-02 |
2011-12-29 |
Daniel J Capon |
Hybrid immunoglobulins with moving parts
|
KR20090082480A
(ko)
|
2006-11-14 |
2009-07-30 |
제넨테크, 인크. |
뉴런 재생의 조절인자
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
AU2007325283B2
(en)
|
2006-11-27 |
2012-08-30 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US8288110B2
(en)
*
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
KR101519672B1
(ko)
|
2006-12-07 |
2015-05-29 |
노파르티스 아게 |
Ephb3에 대한 길항제 항체
|
ES2426158T3
(es)
|
2007-01-22 |
2013-10-21 |
Genentech, Inc. |
Precipitación con polielectrolito y purificación de anticuerpos
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
EP2436781B1
(en)
|
2007-02-22 |
2015-10-07 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
KR20170091174A
(ko)
*
|
2007-04-03 |
2017-08-08 |
옥시레인 유케이 리미티드 |
분자의 글리코실화
|
DK2164992T3
(en)
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
KR20170023212A
(ko)
|
2007-06-07 |
2017-03-02 |
제넨테크, 인크. |
보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법
|
JP5687057B2
(ja)
|
2007-07-09 |
2015-03-18 |
ジェネンテック, インコーポレイテッド |
ポリペプチドの組換え生産中におけるジスルフィド結合還元の防止
|
KR101486615B1
(ko)
|
2007-07-16 |
2015-01-28 |
제넨테크, 인크. |
항-cd79b 항체 및 면역접합체 및 사용 방법
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
CN101361968B
(zh)
|
2007-08-06 |
2011-08-03 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗脂肪肝中的应用
|
US8361465B2
(en)
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
KR20140015166A
(ko)
|
2007-10-30 |
2014-02-06 |
제넨테크, 인크. |
양이온 교환 크로마토그래피에 의한 항체 정제
|
EP2209807A1
(en)
|
2007-11-08 |
2010-07-28 |
Genentech, Inc. |
Anti-factor b antibodies and their uses
|
KR20100097691A
(ko)
|
2007-11-12 |
2010-09-03 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
BRPI0908508A2
(pt)
|
2008-01-24 |
2016-03-22 |
Novo Nordisk As |
anticorpo monoclonal nkg2a anti-humano humanizado
|
TWI607019B
(zh)
|
2008-01-31 |
2017-12-01 |
建南德克公司 |
抗-cd79b抗體及免疫共軛物及使用方法
|
CA2717128A1
(en)
*
|
2008-03-03 |
2009-09-17 |
Chung-Ming Hsieh |
Methods for transforming yeast
|
ES2542308T3
(es)
|
2008-03-10 |
2015-08-04 |
Theraclone Sciences, Inc. |
Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
|
EP2698380A1
(en)
|
2008-03-28 |
2014-02-19 |
Sea Lane Biotechnologies, LLC |
Neutralizing molecules to viral antigens
|
CA3179151A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
RU2553517C2
(ru)
|
2008-05-06 |
2015-06-20 |
Дженентек, Инк. |
Варианты crig с созревшей аффинностью
|
EP3384919A1
(en)
|
2008-06-02 |
2018-10-10 |
Dana Farber Cancer Institute, Inc. |
Cs1 peptides
|
ES2749190T3
(es)
|
2008-08-14 |
2020-03-19 |
Genentech Inc |
Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
|
WO2010034015A2
(en)
|
2008-09-22 |
2010-03-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Modulating the alternative complement pathway
|
BRPI0920027A2
(pt)
|
2008-10-20 |
2015-10-06 |
Abbott Lab |
isolamento e purificação de anticorpos usando cromatografia de afinidade a proteína a
|
KR20110081862A
(ko)
|
2008-10-22 |
2011-07-14 |
제넨테크, 인크. |
축삭 변성의 조절
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
WO2010052556A1
(en)
|
2008-11-06 |
2010-05-14 |
Glenmark Pharmaceuticals S.A. |
Treatment with anti-alpha2 integrin antibodies
|
UY32341A
(es)
|
2008-12-19 |
2010-07-30 |
Glaxo Group Ltd |
Proteínas de unión antígeno novedosas
|
WO2010078376A2
(en)
|
2008-12-30 |
2010-07-08 |
Ventana Medical Systems, Inc. |
Fc-specific polymer-conjugated antibodies and their diagnostic use
|
NZ628987A
(en)
|
2009-02-03 |
2015-11-27 |
Amunix Operating Inc |
Extended recombinant polypeptides and compositions comprising same
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
BRPI1012676A2
(pt)
|
2009-04-01 |
2016-04-05 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
WO2010124163A2
(en)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
JP2012527473A
(ja)
|
2009-05-20 |
2012-11-08 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
NZ596787A
(en)
|
2009-06-08 |
2014-03-28 |
Amunix Operating Inc |
Growth hormone polypeptides and methods of making and using same
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
WO2011008959A1
(en)
|
2009-07-15 |
2011-01-20 |
Abbott Laboratories |
Enhancement of cellular production through mechanotransduction
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
ES2787234T3
(es)
|
2009-09-01 |
2020-10-15 |
Hoffmann La Roche |
Purificación de proteínas potenciada a través de una elución de proteína A modificada
|
EP2473522B1
(en)
|
2009-09-02 |
2016-08-17 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
KR101824743B1
(ko)
|
2009-09-29 |
2018-02-05 |
유니버시테이트 젠트 |
만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
|
US8535912B2
(en)
|
2009-10-15 |
2013-09-17 |
Genentech, Inc. |
Chimeric fibroblast growth factors with altered receptor specificity
|
MX341136B
(es)
|
2009-10-20 |
2016-08-09 |
Abbvie Inc |
Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a.
|
BR112012009257A2
(pt)
|
2009-10-22 |
2016-11-22 |
Genentech Inc |
modulação de degeneração de axônio.
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
WO2011060246A2
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
DK2501805T3
(en)
|
2009-11-19 |
2019-04-15 |
Oxyrane Uk Ltd |
Yeast strains producing mammalian-like complex N-Glycans
|
CN103755809B
(zh)
|
2009-11-30 |
2016-06-01 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
JP5984676B2
(ja)
|
2009-12-18 |
2016-09-06 |
シーエスエル、リミテッド |
ポリペプチドを精製する方法
|
AU2010334383B2
(en)
|
2009-12-21 |
2014-10-02 |
Centre Hospitalier Universitaire Vaudois (Chuv) |
Synergic action of a prolyl protease and tripeptidyl proteases
|
US20110226650A1
(en)
|
2009-12-21 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
US8940303B2
(en)
|
2010-01-28 |
2015-01-27 |
Glaxo Group Limited |
CD127 binding proteins
|
TW201437228A
(zh)
|
2010-02-23 |
2014-10-01 |
Genentech Inc |
用於診斷及治療腫瘤之組合物及方法
|
WO2011104604A2
(en)
|
2010-02-23 |
2011-09-01 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
LT3178851T
(lt)
|
2010-03-31 |
2020-08-10 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antikūnai
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
KR20190067277A
(ko)
|
2010-05-28 |
2019-06-14 |
제넨테크, 인크. |
락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
|
AU2011261161A1
(en)
|
2010-06-01 |
2013-01-10 |
Ludwig Institute For Cancer Research Limited |
Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
|
TW201210612A
(en)
|
2010-06-03 |
2012-03-16 |
Glaxo Group Ltd |
Humanised antigen binding proteins
|
CA2800206C
(en)
|
2010-06-25 |
2018-06-05 |
(Inserm) Institut National De La Sante Et De La Recherche Medicale |
Methods and pharmaceutical compositions for the treatment of respiratory tract infections
|
CA2805035A1
(en)
|
2010-07-22 |
2012-01-26 |
Glaxosmithkline Biologicals S.A. |
Novel antigen binding proteins
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
WO2012021786A2
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
CN102380091A
(zh)
|
2010-08-31 |
2012-03-21 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗病毒性肝炎中的应用
|
PT3556396T
(pt)
|
2010-08-31 |
2022-07-04 |
Scripps Research Inst |
Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
|
AU2011302522A1
(en)
|
2010-09-15 |
2013-05-02 |
Aligna Technologies, Inc. |
Bioproduction of aromatic chemicals from lignin-derived compounds
|
AU2011305754B2
(en)
|
2010-09-20 |
2015-11-05 |
Abbvie Inc. |
Purification of antibodies using simulated moving bed chromatography
|
BR112013007616B1
(pt)
|
2010-09-29 |
2023-01-24 |
Oxyrane Uk Limited |
Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
|
EP2622089B1
(en)
|
2010-09-29 |
2023-11-01 |
Oxyrane UK Limited |
De-mannosylation of phosphorylated n-glycans
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP5696220B2
(ja)
|
2010-10-08 |
2015-04-08 |
シャンハイ クーシン バイオテック カンパニー,リミテッド |
免疫性血小板減少症を診断するための測定方法及びキット、並びに診断組成物の製造におけるモエシン断片の使用
|
EP2624854B1
(en)
|
2010-10-08 |
2016-08-03 |
Shanghai Kexin Biotech Co., Ltd |
Moesin inhibitors and uses thereof
|
US9632098B2
(en)
|
2010-10-08 |
2017-04-25 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments and uses thereof
|
JP5913326B2
(ja)
|
2010-10-08 |
2016-04-27 |
シャンハイ クーシン バイオテック カンパニー,リミテッド |
モエシン断片の診断的および治療的使用
|
CA2814026C
(en)
|
2010-10-08 |
2017-07-11 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments associated with aplastic anemia
|
MX343858B
(es)
|
2010-11-04 |
2016-11-25 |
Boehringer Ingelheim Int |
Anticuerpos anti-il-23.
|
AU2011338892A1
(en)
|
2010-11-05 |
2013-05-23 |
Abbvie Inc. |
Efficient and effective supplement screening for the development of chemically defined media in cell culture
|
SG10201407036YA
(en)
|
2010-11-05 |
2014-12-30 |
Transbio Ltd |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
WO2012064619A1
(en)
*
|
2010-11-10 |
2012-05-18 |
Merck Sharp & Dohme Corp. |
Pichia pastoris loci encoding enzymes in the proline biosynthetic pathway
|
US20140199682A1
(en)
|
2010-11-17 |
2014-07-17 |
Sea Lane Biotechnologies, Llc |
Influenza neutralizing agents
|
CN103429261A
(zh)
|
2010-12-22 |
2013-12-04 |
塞法隆澳大利亚股份有限公司 |
半寿期改进的修饰抗体
|
CA2827301A1
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
US20140056897A1
(en)
|
2011-03-10 |
2014-02-27 |
Hco Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
WO2012128810A1
(en)
|
2011-03-23 |
2012-09-27 |
Abbott Laboratories |
Methods and systems for the analysis of protein samples
|
CN103608038A
(zh)
|
2011-03-31 |
2014-02-26 |
弗·哈夫曼-拉罗切有限公司 |
施用β7整联蛋白拮抗剂的方法
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
US8569462B2
(en)
|
2011-06-03 |
2013-10-29 |
Xoma Technology Ltd. |
Antibodies specific for TGF-beta and methods for treating thereof
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CA2840460C
(en)
|
2011-07-11 |
2022-08-16 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to ox40 and their uses
|
KR20140068877A
(ko)
|
2011-08-17 |
2014-06-09 |
제넨테크, 인크. |
불응성 종양에서의 혈관신생의 억제
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
EA031948B1
(ru)
|
2011-11-16 |
2019-03-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
|
ES2651521T3
(es)
|
2011-12-01 |
2018-01-26 |
Innovent Biologics, Inc. |
Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
|
SG11201403276TA
(en)
|
2011-12-16 |
2014-10-30 |
Braskem Sa |
Modified microorganisms and methods of making butadiene using same
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
AU2012355356B2
(en)
|
2011-12-22 |
2017-10-12 |
Genentech, Inc. |
Ion exchange membrane chromatography
|
US20150031081A1
(en)
|
2011-12-30 |
2015-01-29 |
Oxyrane Uk Limited |
Methods and materials for reducing degradation of recombinant proteins
|
WO2013109342A1
(en)
|
2012-01-19 |
2013-07-25 |
University Of Cincinnati |
Method of treating diabetes using non-glycosylated apolipoprotein a-iv
|
JP2015506950A
(ja)
|
2012-01-31 |
2015-03-05 |
ジェネンテック, インコーポレイテッド |
抗ig−em1’抗体およびそれを用いる方法
|
EP2820047B1
(en)
|
2012-03-01 |
2018-04-25 |
Amgen Research (Munich) GmbH |
Long life polypeptide binding molecules
|
KR20190114003A
(ko)
|
2012-03-15 |
2019-10-08 |
옥시레인 유케이 리미티드 |
폼페병의 치료를 위한 방법 및 물질
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
CA2870769C
(en)
|
2012-04-27 |
2021-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vascular endothelial growth factor antagonists and methods for their use
|
WO2013165791A1
(en)
|
2012-05-03 |
2013-11-07 |
Boehringer Ingelheim International Gmbh |
Anti-il-23p19 antibodies
|
WO2013177118A2
(en)
|
2012-05-21 |
2013-11-28 |
Abbvie Inc. |
Novel purification of non-human antibodies using protein a affinity chromatography
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
US10232019B2
(en)
|
2012-07-25 |
2019-03-19 |
University Of Cincinnati |
Method of treating hyperglycemic disorders using apolipoprotein AIV
|
CA2878695A1
(en)
|
2012-07-25 |
2014-01-30 |
University Of Cincinnati |
Method of treating type i diabetes using apolipoprotein aiv
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
EP2914278B1
(en)
|
2012-11-05 |
2021-06-02 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
WO2014106602A1
(en)
|
2013-01-02 |
2014-07-10 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to tl1a and their uses
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
US20190040368A1
(en)
|
2013-03-05 |
2019-02-07 |
Oxyrane Uk Limited |
Production of catalytically active type i sulfatase
|
SI2968467T1
(sl)
|
2013-03-13 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Pripravki z zmanjšano oksidacijo
|
CN104968362B
(zh)
|
2013-03-13 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
氧化降低的配制剂
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
SG10201913932VA
(en)
|
2013-03-13 |
2020-03-30 |
Genentech Inc |
Antibody formulations
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
EP2970375A1
(en)
|
2013-03-14 |
2016-01-20 |
AbbVie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
US20140271633A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Mammalian cell culture performance through surfactant supplementation of feed media
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
CA2899308C
(en)
|
2013-03-14 |
2017-04-18 |
Abbvie Inc. |
Low acidic species adalimumab compositions and uses thereof
|
BR112015021993A8
(pt)
|
2013-03-15 |
2019-12-03 |
Genentech Inc |
polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
KR102202476B1
(ko)
|
2013-03-15 |
2021-01-12 |
제넨테크, 인크. |
세포 배양 배지 및 항체 생산 방법
|
EP4039281A1
(en)
|
2013-03-15 |
2022-08-10 |
Biomolecular Holdings LLC |
Hybrid immunoglobulin containing non-peptidyl linkage
|
TW201525001A
(zh)
|
2013-03-15 |
2015-07-01 |
Amgen Res Munich Gmbh |
包含n-端abp之單鏈結合分子
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
JP6574754B2
(ja)
|
2013-03-19 |
2019-09-11 |
ベイジン シェノゲン ファーマ グループ リミテッド |
エストロゲン受容体関連疾患を処置するための抗体及び方法
|
RU2015145610A
(ru)
|
2013-03-27 |
2017-05-04 |
Дженентек, Инк. |
Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
|
LT3004162T
(lt)
|
2013-05-31 |
2020-06-10 |
Genentech, Inc. |
Antikūnai prieš ląstelės sienelės teicho rūgštį ir konjugatai
|
JP2016521701A
(ja)
|
2013-06-07 |
2016-07-25 |
ノヴォ ノルディスク アー/エス |
成熟インスリンポリペプチドを作製するための方法
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向cd33及cd3之雙特異性化合物的組合
|
HUE047194T2
(hu)
|
2013-09-27 |
2020-04-28 |
Hoffmann La Roche |
Anti-PDL1 antitest készítmények
|
WO2015069459A1
(en)
|
2013-11-05 |
2015-05-14 |
Novartis Ag |
Organic compounds
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
MX2016007972A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
CN106062005A
(zh)
|
2013-12-30 |
2016-10-26 |
医药生命融合研究团 |
抗krs单克隆抗体及其用途
|
WO2016039801A1
(en)
|
2014-01-31 |
2016-03-17 |
Boehringer Ingelheim International Gmbh |
Novel anti-baff antibodies
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
KR102587838B1
(ko)
|
2014-03-14 |
2023-10-12 |
바이오몰레큘러 홀딩스 엘엘씨 |
비-펩티드 결합을 함유하는 하이브리드 면역글로불린
|
CN111808276A
(zh)
|
2014-03-25 |
2020-10-23 |
豪夫迈·罗氏有限公司 |
制备用于细胞培养基中的泊洛沙姆的方法
|
EP3122377A4
(en)
|
2014-03-27 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Methods for diagnosing and treating inflammatory bowel disease
|
CN106132439A
(zh)
|
2014-03-31 |
2016-11-16 |
豪夫迈·罗氏有限公司 |
包含抗血管发生剂和ox40结合激动剂的组合疗法
|
US8961992B1
(en)
|
2014-04-02 |
2015-02-24 |
Tunitas Therapeutics, Inc. |
Epsigam fusion protein
|
EP3149187B1
(en)
|
2014-05-30 |
2020-04-29 |
Braskem S.A. |
Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
|
EP3145951A1
(en)
|
2014-06-24 |
2017-03-29 |
InSight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
US20170226552A1
(en)
|
2014-07-03 |
2017-08-10 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
WO2016007764A1
(en)
|
2014-07-09 |
2016-01-14 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
|
EP3708679A1
(en)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
EP3174903B1
(en)
|
2014-07-31 |
2024-04-10 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibody construct with enhanced tissue distribution
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
EP3193932B1
(en)
|
2014-09-15 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
WO2016081384A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
MX2017007055A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
|
WO2016120764A1
(en)
|
2015-01-26 |
2016-08-04 |
Centre Hospitalier Universitaire Vaudois (Chuv) |
Aspergillus oryzae prolyl endopeptidases and use thereof in degradation of polypeptides
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
IL307578A
(en)
|
2015-02-04 |
2023-12-01 |
Boehringer Ingelheim Int |
Methods for treating inflammatory diseases
|
EP3262072A1
(en)
|
2015-02-26 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Integrin beta7 antagonists and methods of treating crohn's disease
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
WO2016144773A1
(en)
|
2015-03-06 |
2016-09-15 |
Abbvie Inc. |
Arabinosylated glycoproteins
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
EP3391905A1
(en)
|
2015-04-14 |
2018-10-24 |
Boehringer Ingelheim International GmbH |
Treatment of asthma with anti-il-23a antibodies
|
FI3283524T3
(fi)
|
2015-04-17 |
2023-05-05 |
Amgen Res Munich Gmbh |
Bispesifisiä vasta-ainekonstrukteja cdh3:lle ja cd3:lle
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CA2993276A1
(en)
|
2015-08-11 |
2017-02-16 |
Yong Zheng |
Novel anti-pd-1 antibodies
|
US20190248905A1
(en)
|
2015-09-07 |
2019-08-15 |
Helmholtz Zentrum Muenchen-Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) |
Novel igfr-like receptor and uses thereof
|
TWI733695B
(zh)
|
2015-09-18 |
2021-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
US11040114B2
(en)
|
2015-12-24 |
2021-06-22 |
Oxyrane Uk Limited |
Human alpha-N-acetylgalactosaminidase polypeptide
|
MX2018008063A
(es)
|
2015-12-30 |
2018-11-29 |
Genentech Inc |
Uso de derivados de triptofano para formulaciones de proteina.
|
JP7008023B2
(ja)
|
2015-12-30 |
2022-01-25 |
ジェネンテック, インコーポレイテッド |
低減されたポリソルベート分解を有する製剤
|
AU2017216237B2
(en)
|
2016-02-03 |
2024-04-04 |
Amgen Research (Munich) Gmbh |
PSMA and CD3 bispecific T cell engaging antibody constructs
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
RS62841B1
(sr)
|
2016-02-03 |
2022-02-28 |
Amgen Res Munich Gmbh |
Bcma i cd3 konstrukti antitela koji angažuju bispecifične t ćelije
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CN116196412A
(zh)
|
2016-03-15 |
2023-06-02 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
WO2017161976A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
ES2930351T3
(es)
|
2016-04-15 |
2022-12-09 |
Evive Biotechnology Shanghai Ltd |
Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
|
JP6728392B2
(ja)
|
2016-04-15 |
2020-07-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
炎症性疾患の処置法
|
EP3464354B1
(en)
|
2016-06-02 |
2021-07-28 |
Bloom Diagnostics AG |
Antibodies that bind to human anti-müllerian hormone (amh) and their uses
|
US10519250B2
(en)
|
2016-08-01 |
2019-12-31 |
Xoma (Us) Llc |
Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
US11111313B2
(en)
|
2016-09-20 |
2021-09-07 |
WuXi Biologics Ireland Limited |
Anti-PCSK9 antibodies
|
CA3038679A1
(en)
|
2016-09-28 |
2018-04-05 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
EP3526252A2
(en)
|
2016-10-14 |
2019-08-21 |
Boehringer Ingelheim International GmbH |
Methods of treating diseases with il-23a antibody
|
EP3526248A4
(en)
|
2016-10-17 |
2020-07-08 |
Musc Foundation for Research Development |
COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
|
EP3574007A1
(en)
|
2017-01-30 |
2019-12-04 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel igfr-like 2 receptor and uses thereof
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
JP7216424B2
(ja)
|
2017-03-15 |
2023-02-01 |
チンファ ユニバーシティ |
新規の抗TrkB抗体
|
WO2018182284A1
(ko)
|
2017-03-27 |
2018-10-04 |
재단법인 의약바이오컨버젼스연구단 |
세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
|
EP3601350A1
(en)
|
2017-03-27 |
2020-02-05 |
Boehringer Ingelheim International GmbH |
Anti il-36r antibodies combination therapy
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
BR112019022751A2
(pt)
|
2017-05-05 |
2020-05-19 |
Amgen Inc |
composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
KR20200047660A
(ko)
|
2017-09-01 |
2020-05-07 |
다나-파버 캔서 인스티튜트 인크. |
암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드
|
WO2019089544A1
(en)
|
2017-11-01 |
2019-05-09 |
Tufts Medical Center, Inc. |
Bispecific antibody constructs and methods of use
|
TWI827570B
(zh)
|
2017-12-11 |
2024-01-01 |
美商安進公司 |
雙特異性抗體產品之連續製造製程
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
JP2021514193A
(ja)
|
2018-02-21 |
2021-06-10 |
セルジーン コーポレイション |
Bcma結合抗体及びその使用
|
KR102340989B1
(ko)
|
2018-03-28 |
2021-12-20 |
에이비온 주식회사 |
클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
TWI819011B
(zh)
|
2018-06-23 |
2023-10-21 |
美商建南德克公司 |
以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
|
KR20210027436A
(ko)
|
2018-06-29 |
2021-03-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
자가면역 질환을 치료하는데 사용하기 위한 항-cd40 항체
|
JP2021533149A
(ja)
|
2018-08-08 |
2021-12-02 |
ジェネンテック, インコーポレイテッド |
タンパク質製剤のためのトリプトファン誘導体及びl−メチオニンの使用
|
EP3857230B1
(en)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
WO2020068557A1
(en)
|
2018-09-25 |
2020-04-02 |
BioLegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
WO2020069303A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Antibodies against soluble bcma
|
WO2020077212A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
WO2020083979A1
(en)
|
2018-10-23 |
2020-04-30 |
Glycardial Diagnostics, S.L. |
Antibodies specific for glycosylated apoj and uses thereof
|
WO2020136232A1
(en)
|
2018-12-28 |
2020-07-02 |
Transgene Sa |
Immunosuppressive m2 protein
|
EP3941938A1
(en)
|
2019-03-06 |
2022-01-26 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
CN114096559A
(zh)
|
2019-03-27 |
2022-02-25 |
蒂嘉特克斯公司 |
工程化iga抗体及其使用方法
|
EA202193038A1
(ru)
|
2019-05-09 |
2022-03-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Антитела против sema3a и их применения для лечения заболеваний глаз
|
TW202108627A
(zh)
|
2019-05-24 |
2021-03-01 |
大陸商三優生物醫藥(上海)有限公司 |
新型cldn18.2結合分子
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
MX2022002337A
(es)
|
2019-08-27 |
2022-06-08 |
Tonix Pharma Ltd |
Polipéptidos de tff2 modificados.
|
EP4028416A1
(en)
|
2019-09-10 |
2022-07-20 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
|
US20230125690A1
(en)
|
2019-09-20 |
2023-04-27 |
Jae-sung Bae |
Antibody for detecting acetylation of cox2 protein, and uses thereof
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
CN113461817A
(zh)
|
2020-03-31 |
2021-10-01 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
TW202204601A
(zh)
|
2020-04-15 |
2022-02-01 |
美商建南德克公司 |
銅損失減緩
|
US20210380696A1
(en)
|
2020-05-26 |
2021-12-09 |
Boehringer Ingelheim International Gmbh |
Anti-pd-1 antibodies
|
EP4157875A1
(en)
|
2020-06-02 |
2023-04-05 |
Arcus Biosciences, Inc. |
Antibodies to tigit
|
US20210388064A1
(en)
|
2020-06-15 |
2021-12-16 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus antibodies and fragments thereof
|
CN115916182A
(zh)
|
2020-06-16 |
2023-04-04 |
基因泰克公司 |
用于治疗三阴性乳腺癌的方法和组合物
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
CR20230235A
(es)
|
2020-11-06 |
2023-10-05 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
|
WO2022096698A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
TW202233678A
(zh)
|
2020-11-06 |
2022-09-01 |
德商安美基研究(慕尼黑)公司 |
具有增強的剪切特徵的多肽
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
EP4263597A2
(en)
|
2020-12-18 |
2023-10-25 |
Kiniksa Pharmaceuticals, Ltd. |
Protein compositions and methods for producing and using the same
|
AU2022246675A1
(en)
|
2021-04-02 |
2023-10-19 |
Amgen Inc. |
Mageb2 binding constructs
|
EP4332120A1
(en)
|
2021-04-26 |
2024-03-06 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Bispecific antibody-drug conjugate
|
AU2022313524A1
(en)
|
2021-07-23 |
2024-02-15 |
Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) |
Igfr-l1 antibodies and uses thereof
|
WO2023105087A1
(en)
|
2021-12-10 |
2023-06-15 |
Tubulis Gmbh |
Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
|
EP4238988A1
(en)
|
2022-03-01 |
2023-09-06 |
Consejo Superior De Investigaciones Científicas |
Antibodies against sars-cov-2 and uses thereof
|
WO2023173011A1
(en)
|
2022-03-09 |
2023-09-14 |
Bristol-Myers Squibb Company |
Transient expression of therapeutic proteins
|
WO2024032891A1
(en)
|
2022-08-11 |
2024-02-15 |
Vib Vzw |
Glyco-engineered yeast for therapeutic protein production
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|